Impact of Ageing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Impact of Ageing
Despite the fact that Europe's population is ageing rapidly, the region is astonishingly still underprepared for dealing with the health-related effect of this demographic trend. A major challenge for governments in the EU is meeting rising demand for healthcare whilst tailoring the systems to needs of the elderly.


Pharmaceutical Technology Europe
Volume 23, Issue 12


Nathan Jessop ((Spotlight image) Stockbyte/GettyImages)
By 2025, more than 20% of the European population will be 65 or older, with a particularly rapid increase in the number of people over 80. By 2050, the number of people aged 65 and above is expected to grow by 70% and the number of people aged over 80 by 170% (1).

In 2004, the US National Center for Health Statistics reported that 80% of the elderly population (adults aged 65 years and older) took at least one prescription drug in the prior month. Its survey revealed that around half of the individuals in the same age group reported taking three or more prescription drugs and that this statistic represented an increase of nearly 50% over the prior 5–10 years (2). The issue of polypharmacy is also of particular concern in the elderly, who, compared with younger individuals, tend to have more disease conditions for which medicines are required (3). While pan-European figures are hard to come by, these insights into trends in healthcare usage by the elderly studied elsewhere in the world should be considered relevant for the future of healthcare in Europe.

Optimism and harsh realities

The European Commission's (EC) official position is to actively support Member States in their efforts to promote healthy ageing through dedicated initiatives to improve the health of older people. An ageing population in good health will also mean less strain on health systems and fewer people retiring from work due to ill health. At present, the European Innovation Partnership on Active and Healthy Ageing aims to ensure that the average European citizen has two more active and healthy years to live by 2020 (4). The EC have termed ageing as an opportunity for the region rather than a hindrance. The Partnerships Steering Group was set up in May 2011, and is made up of more than 30 stakeholders representing the health and ageing area, including Member States and regions, organisations representing older patients, nurses, carers and doctors, hospital representatives, academics, industry and venture capitalists organisations. It has already announced that in 2012, it will launch calls for involvement of stakeholders beyond those that participated in the Steering Group to implement together the priorities and actions identified in a Strategic Implementation Plan that it adopted at a meeting in November 2011 (4).

While those behind the initiative push the project forward, their optimism sits in contrast to the current realities because funding and resourcing healthcare systems through societies with smaller workforces is becoming extremely difficult. Most governments have no choice but to make cutbacks in the current, uncertain economic environment, which affects the ability to deliver effective healthcare services for the growing elderly population. For example, the EU recently and dramatically revised its growth forecast for the Eurozone in 2012, from 1.8% to a mere 0.5% (5). Such financial predictions will do little to convince nervous politicians to provide additional investment for initiatives to boost healthcare systems that are already underfunded.

The ominous situation in Greece illustrates the difficulties that can arise in the current economic climate. As a result of the economic meltdown, doctors' wages in the public system have been cut in line with those of other government workers, and hospitals are at risk of being merged and face regular shortages of materials. Even patients who should be entitled to reduced or free medication often cannot find pharmacists to provide them and are instead asked to pay the cost up front and then seek reimbursement.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here